Genetic Technologies (NASDAQ:GENE) and Crispr Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Insider & Institutional Ownership

2.7% of Genetic Technologies shares are held by institutional investors. Comparatively, 49.8% of Crispr Therapeutics shares are held by institutional investors. 21.4% of Crispr Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Genetic Technologies has a beta of 3.7, indicating that its share price is 270% more volatile than the S&P 500. Comparatively, Crispr Therapeutics has a beta of 3.2, indicating that its share price is 220% more volatile than the S&P 500.

Profitability

This table compares Genetic Technologies and Crispr Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genetic Technologies N/A N/A N/A
Crispr Therapeutics -5.30% -2.60% -2.05%

Earnings & Valuation

This table compares Genetic Technologies and Crispr Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genetic Technologies $20,000.00 868.77 -$4.60 million N/A N/A
Crispr Therapeutics $3.12 million 1,031.99 -$164.98 million ($3.44) -16.96

Genetic Technologies has higher earnings, but lower revenue than Crispr Therapeutics.

Analyst Recommendations

This is a summary of current recommendations for Genetic Technologies and Crispr Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genetic Technologies 0 0 0 0 N/A
Crispr Therapeutics 1 1 12 0 2.79

Crispr Therapeutics has a consensus price target of $72.86, indicating a potential upside of 24.92%. Given Crispr Therapeutics’ higher possible upside, analysts clearly believe Crispr Therapeutics is more favorable than Genetic Technologies.

Summary

Crispr Therapeutics beats Genetic Technologies on 6 of the 11 factors compared between the two stocks.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.



Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Source link